An indirect comparison of acalabrutinib with and without obinutuzumab vs zanubrutinib in treatment-naive CLL
Adam S. Kittai(Icahn School of Medicine at Mount Sinai), Matthew S. Davids(Dana-Farber Cancer Institute), John N. Allan(Cornell University), Jack Roos(AstraZeneca (United States)), Fady Fam(AstraZeneca (United Kingdom)), Miguel Miranda(AstraZeneca (United Kingdom)), Alan SM Yong(AstraZeneca (United States)), Helen Bridge(AstraZeneca (United Kingdom)), Vikram Shetty(AstraZeneca (United States)), Dan James, Alan P Skarbnik(Novant Health)
Cited by 18
Related Papers
PI3K/AKT/mTOR signaling transduction pathway and targeted therapies in cancer
|Molecular Cancer|2023|1.9k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|Journal of Clinical Oncology|2017|752
Small molecules, big impact: 20 years of targeted therapy in oncology
|The Lancet|2020|606
Ipilimumab for Patients with Relapse after Allogeneic Transplantation
|New England Journal of Medicine|2016|601